Philips showcases imaging, physiology advances at EuroPCR 2026
PUBT·05/18/2026 15:00:32
Listen to the news
- Philips will showcase imaging, physiology, and AI-enabled guidance for complex PCI at EuroPCR 2026 in Paris on May 19-22.
- The company will run a PCI-focused symposium, “Contemporary Workflow for Class IA PCI,” on May 19 from 13:10 to 14:40.
- A structural heart symposium, “Seeing differently, treating better,” is scheduled for May 20 from 16:35 to 18:05.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Royal Philips NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605181100OMX_____CNEWS_EN_GNW1001182606_en) on May 18, 2026, and is solely responsible for the information contained therein.
Contact Us
Contact Number :+852 3852 8500Monday 7:00 AM - Saturday 9:00 AM (HKT)
Service Email :service@webull.hkOnline Support: Monday - Friday: 9:00 - 16:00; 22:30 - 5:00 (HKT)
Business Cooperation :marketinghk@webull.hkRisk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language
English
©2026 Webull Securities Limited. All rights reserved.